Cumberland Pharmaceuticals Inc. (CPIX) Income Statement
CPIX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCPIX revenue and net income
Where CPIX's revenue goes
2025Each bar shows an amount and its share of revenue. CPIX kept −6.4% of revenue as net income.
CPIX profit margins
CPIX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +17.6% | +2.0% | +3.5% | +2.9% |
| Gross profit | +21.0% | +4.8% | +5.6% | +2.9% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CPIX quarterly EPS vs estimates
Cumberland Pharmaceuticals beat the analyst EPS estimate in 0 of the last 4 quarters. Next report: November 3, 2026.
CPIX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $36.0M | $37.4M | $34.4M | $40.7M | $41.2M | $33.0M |
| Cost of revenue | $6.7M | $6.6M | $6.1M | $9.1M | $8.8M | $8.7M | $7.4M | $7.4M | $7.4M | $6.0M |
| Gross profit | $37.9M | $31.3M | $33.5M | $32.9M | $27.2M | $28.8M | $27.0M | $33.4M | $33.8M | $27.1M |
| Research & development | $5.6M | $4.8M | $5.8M | $6.7M | $5.7M | $5.8M | $6.9M | $7.3M | $3.9M | $3.2M |
| Sales, general & admin | $31.0M | $28.1M | $29.1M | $26.8M | $24.8M | $25.0M | $25.3M | $30.7M | $31.5M | $23.1M |
| Total operating expenses | $40.6M | $37.7M | $43.0M | $38.6M | $34.9M | $35.2M | $36.3M | $40.8M | $37.9M | $28.5M |
| Operating income | −$2.8M | −$6.4M | −$9.6M | −$5.7M | −$7.7M | −$6.4M | −$9.3M | −$7.4M | −$4.1M | −$1.4M |
| Interest income | $476,748 | $334,444 | $251,550 | $98,405 | $26,081 | $75,345 | $243,364 | $564,484 | $299,326 | $204,661 |
| Interest expense | $495,990 | $605,508 | $667,861 | $585,995 | $98,031 | $263,627 | $246,186 | $195,848 | $92,904 | $106,392 |
| Income before taxes | −$2.8M | −$6.5M | −$6.3M | −$5.6M | −$5.6M | −$6.6M | −$9.3M | −$7.0M | −$3.9M | −$1.3M |
| Income taxes | $40,256 | −$22,669 | $45,769 | $68,850 | $34,891 | $55,902 | −$79,316 | $16,636 | $4.2M | −$330,924 |
| Net income | −$2.8M | −$6.5M | −$6.3M | −$5.6M | −$3.5M | −$3.3M | −$3.5M | −$7.0M | −$8.0M | −$944,683 |
| EBITDA | $3.0M | $182,422 | $153,318 | $332,919 | −$857,833 | −$1.6M | −$4.6M | −$8.2M | −$1.1M | $1.2M |
| EPS (diluted) | −$0.19 | −$0.46 | −$0.15 | −$0.26 | −$0.18 | $0.12 | $0.31 | −$0.03 | −$0.40 | −$0.06 |
| Gross margin | 85.0% | 82.6% | 84.7% | 78.3% | 75.5% | 76.9% | 78.4% | 81.9% | 82.1% | 82.0% |
| Operating margin | −6.3% | −17.0% | −24.2% | −13.6% | −21.3% | −17.0% | −27.0% | −18.1% | −9.9% | −4.3% |
| Net margin | −6.4% | −17.1% | −15.9% | −13.3% | −9.7% | −8.9% | −10.3% | −17.1% | −19.4% | −2.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $166,458 | $9.1M | $13.7M | $8.3M | $10.8M | $11.7M | $10.4M | $9.1M | $9.8M | $8.5M | $9.4M | $10.1M |
| Cost of revenue | $37,404 | $1.9M | $2.2M | $988,760 | $2.0M | $1.4M | $2.0M | $1.3M | $1.7M | $1.6M | $1.5M | $1.8M |
| Gross profit | $129,054 | $7.2M | $11.4M | $7.3M | $8.8M | $10.3M | $8.5M | $7.8M | $8.1M | $6.9M | $7.8M | $8.3M |
| Research & development | $772,162 | $1.5M | $1.5M | $1.3M | $1.5M | $1.3M | $1.3M | $1.3M | $1.1M | $1.2M | $1.3M | $1.9M |
| Sales, general & admin | $2.5M | $7.6M | $10.2M | $7.0M | $7.1M | $6.7M | $7.5M | $7.1M | $7.0M | $6.5M | $8.2M | $7.1M |
| Total operating expenses | $3.3M | $10.3M | $12.8M | $9.3M | $9.6M | $9.0M | $10.3M | $9.5M | $9.2M | $8.8M | $14.0M | $10.2M |
| Operating income | −$3.2M | −$3.1M | −$1.4M | −$2.0M | −$747,478 | $1.3M | −$1.8M | −$1.7M | −$1.0M | −$1.9M | −$6.2M | −$1.9M |
| Interest income | $60,884 | $78,031 | $91,967 | $131,583 | $127,489 | $125,709 | $106,667 | $69,190 | $61,841 | $96,746 | $81,000 | $98,603 |
| Interest expense | $724 | $85,839 | $112,942 | $109,699 | $109,547 | $163,802 | $223,261 | $137,374 | $126,347 | $118,526 | $178,792 | $110,081 |
| Income before taxes | −$3.1M | −$3.1M | −$1.4M | −$1.9M | −$729,536 | $1.3M | −$2.0M | −$1.5M | −$1.1M | −$1.9M | −$6.3M | −$1.1M |
| Income taxes | $3,870 | $3,871 | $23,245 | $5,670 | $5,671 | $5,670 | −$56,996 | $11,442 | $11,443 | $11,442 | $24,956 | $6,938 |
| Net income | −$4.1M | −$3.1M | −$1.4M | −$1.9M | −$740,740 | $1.3M | −$1.9M | −$1.5M | −$1.1M | −$1.9M | −$6.3M | −$1.0M |
| EBITDA | −$3.1M | −$1.5M | $47,844 | −$510,689 | $699,114 | $2.7M | $46,207 | $13,067 | $459,783 | −$336,635 | −$4.0M | $540,559 |
| EPS (diluted) | −$0.20 | −$0.22 | −$0.09 | −$0.13 | −$0.05 | $0.08 | −$0.14 | −$0.11 | −$0.08 | −$0.14 | −$0.44 | $0.02 |
| Gross margin | 77.5% | 78.8% | 83.6% | 88.1% | 81.4% | 87.8% | 81.1% | 85.4% | 82.6% | 81.5% | 83.6% | 82.5% |
| Operating margin | −1,898.7% | −34.3% | −10.0% | −23.7% | −6.9% | 11.0% | −17.7% | −18.6% | −10.4% | −22.0% | −66.1% | −18.5% |
| Net margin | −2,472.5% | −34.4% | −10.3% | −23.4% | −6.8% | 10.7% | −18.2% | −17.0% | −11.0% | −22.9% | −67.3% | −10.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CPIX's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CPIX financial results
In fiscal year 2025 (ended December 31, 2025), Cumberland Pharmaceuticals reported revenue of $44.5 million, up 17.6% from the year before. It had a net loss of $2.8 million, a net profit margin of −6.4%. Diluted earnings per share came to −$0.19. Over five years revenue grew at an average rate of 3.5% a year.
See the CPIX stock overview for the latest quote and news, or the CPIX chart for price history and technical indicators.
CPIX income statement FAQ
What is Cumberland Pharmaceuticals's annual revenue?
Cumberland Pharmaceuticals reported total revenue of $44.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 17.6% from $37.9 million the previous year.
Is Cumberland Pharmaceuticals profitable?
No. Cumberland Pharmaceuticals reported a net loss of $2.8 million in fiscal 2025, a net profit margin of −6.4%; its operating margin was −6.3%.
What is Cumberland Pharmaceuticals's gross margin?
Cumberland Pharmaceuticals's gross margin was 85.0% in fiscal 2025: for every $100 of revenue, Cumberland Pharmaceuticals kept $85 after the direct cost of its products and services.
How much does Cumberland Pharmaceuticals spend on research and development?
Cumberland Pharmaceuticals spent $5.6 million on research and development in fiscal 2025, 12.5% of revenue.
How fast is Cumberland Pharmaceuticals growing?
Revenue grew 3.5% a year on average over the last five fiscal years, from $37.4 million to $44.5 million.
What are Cumberland Pharmaceuticals's earnings per share?
Cumberland Pharmaceuticals earned $-0.19 per diluted share in fiscal 2025, compared with $-0.46 a year earlier.
When will Cumberland Pharmaceuticals report its next earnings?
Cumberland Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Cumberland Pharmaceuticals's fiscal year end?
Cumberland Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.